Exparel

In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...

Brean Capital has downgraded Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Hold from Buy after the FDA said it is evaluating adverse event reports of local anesthetic systemic toxicity (LAST) with company's drug Exparel. "We are downgrading Pacirato Hold from Buy for what we believe will amount to...

Shibani Malhotra of Nomura is expecting the specialty pharmaceutical and generics "merger frenzy" will continue into 2016. Malhotra argued that companies with access to capital are now "more likely" to pursue deals, be it either friendly or hostile. However, Malhotra cautioned that investor...